Search Results for "Contraceptives"
Sort by relevance | Sort by date
Searched for Contraceptives. Results 1 to 10 of 40 total matches.

Choice of Contraceptives

The Medical Letter on Drugs and Therapeutics • Sep 14, 2015  (Issue 1477)
: 800-211-2769 Choice of Contraceptives Implants, intrauterine devices (IUDs), and sterilization ...
Implants, intrauterine devices (IUDs), and sterilization are the most effective contraceptive methods available. Pills, patches, rings, and injectables, when used correctly, are also highly effective in preventing pregnancy. Barrier and fertility-based methods have the highest rates of failure.
Med Lett Drugs Ther. 2015 Sep 14;57(1477):127-32 | Show Introduction Hide Introduction

Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive

The Medical Letter on Drugs and Therapeutics • Jul 08, 2013  (Issue 1420)
: 800-211-2769 Quartette: An Ascending-Dose, Extended-Cycle Oral Contraceptive The FDA has approved ...
The FDA has approved Quartette (Teva), an extended-cycle combination oral contraceptive containing increasing doses of the estrogen ethinyl estradiol (EE) combined with the progestin levonorgestrel (LNG). The rationale is that a gradual increase in the EE dose may reduce unscheduled bleeding or spotting, a common adverse effect of extended-cycle oral contraceptives.
Med Lett Drugs Ther. 2013 Jul 8;55(1420):54-5 | Show Introduction Hide Introduction

In Brief: Plan B One-Step OTC

The Medical Letter on Drugs and Therapeutics • Jun 24, 2013  (Issue 1419)
for emergency contraception as two 0.75-mg tablets taken 12 hours apart (generic formulations of Plan B ...
The progestin levonorgestrel is available over the counter for emergency contraception as two 0.75-mg tablets taken 12 hours apart (generic formulations of Plan B) and as a single 1.5-mg tablet taken once (Plan B One-Step, and generics). A third emergency contraceptive, ulipristal (Ella – Watson), is available with a prescription.1 It appears that, pursuant to a court order, Plan B One-Step (but not the generic products), which was previously available over the counter from a pharmacist only for women 17 years and older, will now be available directly from pharmacy shelves with no age...
Med Lett Drugs Ther. 2013 Jun 24;55(1419):52 | Show Introduction Hide Introduction

A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)

The Medical Letter on Drugs and Therapeutics • Mar 18, 2013  (Issue 1412)
progestin, over a period of 3 years. A table summarizing contraceptive methods available in the US appears ...
The FDA recently approved Skyla (Bayer), the first new intrauterine device (IUD) in the US in 12 years. It releases levonorgestrel, a synthetic progestin, over a period of 3 years. A table summarizing contraceptive methods available in the US appears on page 22.
Med Lett Drugs Ther. 2013 Mar 18;55(1412):21-2 | Show Introduction Hide Introduction

Liletta - A Third Levonorgestrel-Releasing IUD

The Medical Letter on Drugs and Therapeutics • Jul 06, 2015  (Issue 1472)
-term contraception and a rapid return to fertility after removal. ParaGard T 380A, a copper-containing IUD, Mirena ...
The FDA has approved Liletta, an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy for up to 3 years. The fourth IUD to be approved in the US, and the third that releases levonorgestrel, Liletta is comarketed by Actavis and Medicines360, a nonprofit women's health pharmaceutical company. The wholesale cost of Liletta is similar to that of other IUDs (see Table 1), but the manufacturer offers programs that significantly reduce the cost for commercially-insured patients and clinics serving low-income women.
Med Lett Drugs Ther. 2015 Jul 6;57(1472):99-100 | Show Introduction Hide Introduction

Kyleena - Another Hormonal IUD

The Medical Letter on Drugs and Therapeutics • Feb 27, 2017  (Issue 1515)
for up to 5 years of use. IUDs — IUDs provide convenient, long-term contraception and a rapid return ...
The FDA has approved Kyleena (Bayer), an intrauterine device (IUD) that releases the synthetic progestin levonorgestrel, for prevention of pregnancy. It is the fourth levonorgestrel-releasing IUD to be approved in the US. Like Mirena, which has been available since 2000, Kyleena is approved for up to 5 years of use.
Med Lett Drugs Ther. 2017 Feb 27;59(1515):38-9 | Show Introduction Hide Introduction

Miltefosine (Impavido) for Leishmaniasis

The Medical Letter on Drugs and Therapeutics • Sep 15, 2014  (Issue 1451)
before starting treatment with miltefosine. They should use effective contraception while taking ...
The FDA has approved miltefosine (Impavido – Knight Therapeutics), an oral alkylphosphocholine analog, for treatment of visceral, cutaneous, and mucosal leishmaniasis caused by some Leishmania species. It is the first drug to be approved by the FDA for treatment of cutaneous and mucosal leishmaniasis and the first oral drug to be approved for treatment of visceral leishmaniasis.
Med Lett Drugs Ther. 2014 Sep 15;56(1451):89-90 | Show Introduction Hide Introduction

Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein (online only)

The Medical Letter on Drugs and Therapeutics • Mar 27, 2017  (Issue 1517)
estrogens (hormone thiabendazole rifampin replacement therapy vemurafenib smoking and oral contraceptives ...
View the Inhibitors and Inducers of CYP Enzymes and P-Glycoprotein table
Med Lett Drugs Ther. 2017 Mar 27;59(1517):e56-57 | Show Introduction Hide Introduction

Topiramate Extended-Release (Trokendi XR) for Epilepsy

The Medical Letter on Drugs and Therapeutics • Oct 28, 2013  (Issue 1428)
of estrogens in combination oral contraceptives; decreased contraceptive efficacy and/or increased ...
The FDA has approved a once-daily extended-release (ER) formulation of the antiepileptic topiramate (Trokendi XR – Supernus) for initial monotherapy in patients ≥10 years old with partial onset seizures or primary generalized tonic-clonic seizures and for adjunctive therapy in patients ≥6 years old with partial onset seizures, primary generalized tonic-clonic seizures, or seizures associated with Lennox-Gastaut syndrome. Topiramate has been available for many years as an immediate-release (IR) formulation (Topamax, and generics) for the same indications in patients ≥2 years...
Med Lett Drugs Ther. 2013 Oct 28;55(1428):87-8 | Show Introduction Hide Introduction

Perampanel (Fycompa) for Epilepsy

The Medical Letter on Drugs and Therapeutics • Feb 03, 2014  (Issue 1435)
contraceptives, perampanel 12 mg/day decreased levonorgestrel levels by 40%; nonhormonal forms of contraception ...
Perampanel (per am’ pa nel; Fycompa – Eisai), a first-in-class noncompetitive AMPA receptor antagonist, has been approved by the FDA for adjunctive treatment of partial-onset seizures in patients ≥12 years old. New drugs for epilepsy are often initially approved by the FDA as adjunctive treatment for partial seizures.
Med Lett Drugs Ther. 2014 Feb 3;56(1435):9-10 | Show Introduction Hide Introduction